Pillar Biosciences’ FDA-Approved Solid Tumor NGS Kit oncoReveal™ CDx Launched at Molecular Pathology Laboratory Network, Inc.
Pillar Biosciences, Inc., the leader in Decision Medicine™, has announced that Molecular Pathology Laboratory Network, Inc. (MPLN) is now the first national molecular reference laboratory to verify and launch oncoReveal™ CDx.
